0001140361-26-021036
SEC filingBridgeBio Pharma submitted an NDA to the FDA for encaleret as a potential first-approved therapy for autosomal dominant hypocalcemia type 1 (ADH1), based on positive Phase 3 CALIBRATE trial results showing 76% of encaleret-treated patients achieved dual serum and urine calcium normalization at Week 24 versus 4.4% on standard of care.
This NDA submission represents a pivotal regulatory and commercial inflection point for BridgeBio, centered on encaleret’s potential to become the first disease-modifying therapy for ADH1 — a rare, genetically driven disorder with no currently approved treatment. The strength of the Phase 3 CALIBRATE data underpins the filing: statistically robust efficacy across dual calcium targets, rapid pharmacodynamic onset, sustained benefit through 24 weeks, and restoration of endogenous parathyroid hormone — all suggesting mechanistic validation of encaleret’s calcium-sensing receptor modulation. With Fast Track and Orphan Drug designations already secured, priority review eligibility further supports an accelerated FDA timeline. The anticipated U.S. launch in early 2027 positions encaleret for near-term revenue generation, particularly given the disclosed ~2,000 diagnosed U.S. ADH patients (based on claims since October 2023) and growing diagnostic awareness. Strategically, BridgeBio is expanding encaleret’s development footprint beyond ADH1 into pediatric ADH1 (CALIBRATE-PEDS, ongoing) and chronic hypoparathyroidism (RECLAIM-HP, initiating Summer 2026), leveraging proof-of-concept evidence of PTH-independent renal calcium handling effects. While forward-looking statements caution against overreliance on timelines and approval assumptions, the completeness of the clinical dataset, alignment with regulatory feedback implied by designation status, and clear commercial framing signal high strategic and valuation relevance for investors.